HC Wainwright & Co. Initiates Coverage On Ensysce Biosciences with Buy Rating, Announces Price Target of $9
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has initiated coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and a price target of $9.
July 03, 2023 | 10:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences has been given a Buy rating by HC Wainwright & Co. with a price target of $9.
The Buy rating and price target of $9 announced by HC Wainwright & Co. for Ensysce Biosciences indicates a positive outlook for the company. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100